Verseon (VSN) Share Price, News & Analysis

Company Overview

Verseon Corporation, a pharmaceutical company, designs and develops novel therapeutics for various diseases in the United States. The company is involved in developing oral anticoagulants for various cardiovascular indications with novel pharmacology; kallikrein inhibitors for the treatment of diabetic macular edema and hereditary angioedema; and novel angiogenesis inhibitors for the treatment of solid tumors. Verseon Corporation was founded in 2002 and is headquartered in Fremont, California.

Key Stats

• Today's Range: 74 to 74
• 50-Day Range: 74 to 74
• 52-Week Range: 72.50 to 146.50
• Volume: 3,000 shs
• Average Volume: 75,334 shs
• Market Capitalization: £112.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VSN Stock Analysis - Frequently Asked Questions

How have VSN shares performed this year?

Verseon's stock was trading at GBX 74 at the beginning of 2024. Since then, VSN stock has increased by 0.0% and is now trading at GBX 74.
View the best growth stocks for 2024 here.

How do I buy shares of Verseon?

Shares of VSN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Verseon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verseon investors own include Unity Biotechnology (UBX), Constellation Brands (STZ), NVIDIA (NVDA) and Netflix (NFLX).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:VSN
• CUSIP: N/A
• CIK: N/A
• Web: www.verseon.com
• Phone: +1-510-2259000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 74.84
• Current Ratio: 3.36
• Quick Ratio: 3.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 11.19 per share
• Price / Cash Flow: 6.61
• Book Value: GBX 21 per share
• Price / Book: 3.52

Miscellaneous

• Outstanding Shares: 151,674,000
• Free Float: N/A
• Market Cap: £112.24 million
• Optionable: Not Optionable
• Beta: N/A